HDAC6 inhibitor KA2507

Drug Overview

The HDAC6 inhibitor KA2507 is a first-in-class, orally bioavailable, and highly selective small-molecule inhibitor of the histone deacetylase 6 (HDAC6) enzyme. In the competitive landscape of epigenetic medicine, KA2507 represents a significant departure from older “pan-HDAC” inhibitors (such as Vorinostat). While earlier drugs targeted multiple classes of HDAC enzymes—often leading to severe heart and bone marrow toxicities—KA2507 is engineered as a “surgical” tool. It specifically blocks the HDAC6 isoform while leaving the Class I HDACs (HDAC 1, 2, and 3) untouched. This is critical because Class I enzymes are essential for the survival of healthy cells.

KA2507 was designed to directly disrupt cancer cell survival and reset the external immune environment surrounding the tumor. It is particularly promising for “cold” tumors—cancers the immune system ignores—by making them “visible” to T-cells. By focusing on the unique cytoplasmic role of HDAC6, this drug aims to provide a more tolerable and effective option for patients with hard-to-treat solid tumors.

• Generic Name: KA2507.
• Drug Class: Selective Histone Deacetylase 6 (HDAC6) Inhibitor / Immunotherapy “Primer.”
• Target: HDAC6 (primarily localized in the cytoplasm).
• Route of Administration: Oral (Capsule).
• FDA Approval Status: Investigational. As of March 2026, KA2507 has not received FDA approval. It has successfully completed Phase I safety trials and is currently being evaluated in Phase II clinical studies (such as the NCT04186156 trial) for advanced biliary tract cancers and adenoid cystic carcinoma.

What Is It and How Does It Work? (Mechanism of Action)

KA2507 functions through a unique dual-action mechanism that disrupts the cancer cell’s structural framework while lowering its “immune cloaking” device.

The Cytoplasmic Target: HDAC6

While most HDACs modify DNA packaging inside the nucleus, HDAC6 is primarily found in the cytoplasm. It acts on non-histone proteins vital for the cell’s structural operations. Its most notable target is α-tubulin, which forms the building blocks of microtubules—the cell’s internal transport system.

Molecular Level Mechanisms

1. Surgical Selective Inhibition: KA2507 binds to the catalytic domain of HDAC6 with roughly 118-fold greater selectivity than other iso forms. This precision prevents the common “class-effect” toxicities of earlier drugs, such as heart rhythm changes (QT prolongation).
2. Tubulin Hyperacetylation: By blocking HDAC6, KA2507 causes a rapid accumulation of acetyl groups on α-tubulin. This “over-acetylation” clogs the cell’s internal transport and movement machinery. For a cancer cell, this means it can no longer effectively change its shape to migrate or metastasize.
3. Protein Degradation: HDAC6 regulates the acetylation of Heat Shock Protein 90 (HSP90). When KA2507 inhibits this, HSP90 can no longer protect proteins the cancer needs to survive. This triggers the Unfolded Protein Response (UPR), causing the cancer cell to self-destruct.
4. Immune Re-sensitization: The drug increases the expression of MHC Class I proteins on the surface of the tumor. These are the “ID badges” that allow the immune system’s T-cells to identify a cell as cancerous.
5. Lowering Immune Brakes: KA2507 decreases levels of PD-L1 and STAT-3, which tumors use to paralyze the immune system. By removing these “brakes,” the drug “primes” the tumor to be destroyed by the body’s natural defenses.

FDA Approved Clinical Indications

There are currently no FDA-approved indications for KA2507.

The current clinical research efforts and Phase II trials are focused on rare or “orphan” cancers where new options are desperately needed:

• Advanced Biliary Tract Cancer (BTC): Including cholangiocarcinoma and gallbladder cancer. Research focuses on patients whose disease has progressed despite standard chemotherapy.
• Refractory Solid Tumors: Including Adenoid Cystic Carcinoma (ACC) and salivary gland cancers, which are often slow-growing but resistant to standard chemotherapy.
• Metastatic Melanoma: Investigated in combination with PD-1 inhibitors to see if KA2507 can overcome developed resistance to standard immunotherapy.

Dosage and Administration Protocols

Because KA2507 is an investigational drug, the dosage is strictly controlled within registered clinical trials.

Clinical Efficacy and Research Results

Clinical data from 2024 through early 2026 has highlighted the stability KA2507 can provide to patients with rare, resistant cancers.

• Disease Stabilization (SD): In the Phase I study (NCT03008018), approximately 35% of patients with heavily pre-treated, metastatic solid tumors achieved Stable Disease (SD).
• Durable Responses in ACC: Patients with Adenoid Cystic Carcinoma showed remarkable clinical benefit. In several cases, patients remained on the drug for over 12 to 18 months without tumor growth.
• Target Validation: Pharmacodynamic analysis confirmed that the 800 mg BID dose successfully increased tubulin acetylation in peripheral T-cells, proving the drug hits its molecular target at clinical doses.

Safety Profile and Side Effects

The primary advantage of KA2507 over its predecessors is its significantly improved safety profile. By sparing Class I HDAC enzymes, it avoids the systemic toxicity that made older HDAC inhibitors difficult to tolerate.

Common Side Effects (>20%):

• Gastrointestinal Effects: Mild nausea or loose stools (typically Grade 1), which are usually manageable without stopping treatment.
• Fatigue: A general sense of tiredness or low energy.
• Xerostomia: Dry mouth.
• Headache.

Serious Risks and Monitoring:

• Liver Function: While rare, elevations in liver enzymes (ALT/AST) require regular monitoring of the liver panel.
• Platelet Monitoring: Periodic blood counts are performed to ensure platelets remain at safe levels, though bone marrow suppression is minimal.
• Selective Advantage: Critically, clinical trials thus far have shown no observations of severe cardiotoxicity (heart rhythm disturbances) typical of first-generation HDAC inhibitors.

Research Areas

In Stem Cell and Regenerative Medicine, KA2507 is an invaluable tool for studying “Primary Ciliary Restoration.” Primary cilia are hair-like “cellular antennas” that allow cells to sense their environment. In many aggressive cancers, such as bile duct cancer, these antennas are lost, causing the cell to lose its “sense of place” and become malignant. Researchers have discovered that inhibiting HDAC6 with KA2507 can restore the primary cilia on these cells. This effectively “reminds” the cancer cell how to be a healthy cell again. This research is a cornerstone of “differentiation therapy,” using drugs to “re-educate” cancer cells back into healthy, functioning tissue.

Patient Management and Practical Recommendations

Pre-treatment Tests:

• Baseline Imaging (CT or MRI): To establish the size of the tumor before the first dose.
• Standard Blood Work: Including a Complete Blood Count (CBC) and a Comprehensive Metabolic Panel (CMP).

Precautions:

• The Importance of Adherence: Because the drug has a very short half-life (~3 hours), missing a dose can significantly lower its effectiveness.
• Combination Monitoring: If taking KA2507 with immunotherapy, doctors monitor for “pseudo-progression,” where a tumor looks larger on a scan because of immune cell infiltration.

“Do’s and Don’ts” List:

• DO take your doses at the same time every morning and evening (e.g., 8:00 AM and 8:00 PM).
• DO stay well-hydrated throughout the day.
• DON’T stop the medication without consulting your oncologist, even if you have mild nausea.
• DON’T take grapefruit products or herbal supplements like St. John’s Wort, as these can alter how your liver processes the drug.

Legal Disclaimer

The information provided is for educational purposes only and does not constitute medical advice. HDAC6 inhibitor KA2507 is an investigational agent and is not approved by the FDA for any indication. It is available only through participation in approved clinical trials. Always consult with a qualified hematologist-oncologist regarding your diagnosis and treatment options.